A Study to Evaluate the Effects of Efalizumab on Immune Responses in Subjects With Moderate Plaque Psoriasis
NCT00382512
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
60
Enrollment
INDUSTRY
Sponsor class
Conditions
Plaque Psoriasis
Interventions
DRUG:
Raptiva (efalizumab)
Sponsor
Genentech, Inc.